Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Ex vivo evaluation of Newcastle disease virus to enhance natural killer cell function against acute myeloid leukemia cells.

Scientific reports·2026
Same author

Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions.

Molecular biology reports·2026
Same author

Combined PD-1 and TIGIT blockade via siRNA enhances anti-leukemic T-cell function and promotes AML cell apoptosis.

Scientific reports·2026
Same author

Deregulation of stemness and senescence genes in bone marrow mesenchymal stem cells of multiple myeloma: implications for therapeutic approaches.

Blood research·2026
Same author

Lipid nanoparticle mediated delivery of Anti-CD19 CAR mRNA to umbilical cord blood NK cells for targeting CD19⁺ primary B-ALL cells.

Current research in translational medicine·2025
Same author

Prophylactic infusion of donor derived CMV specific T cells for the prevention of CMV reactivation following allogeneic HSCT.

Scientific reports·2025
Same journal

DC-intrinsic SHP1 restrains central memory CD8⁺ T cell formation via the TCF-1/Wnt/β-Catenin axis.

Medical oncology (Northwood, London, England)·2026
Same journal

Site-specific trastuzumab Fab-DM1 via butelase-1 with ABD fusion for potent HER2-positive tumor control.

Medical oncology (Northwood, London, England)·2026
Same journal

Unraveling the link between genomic instability and tumor immune evasion in oral squamous cell carcinoma: Role of CBMN assay and emerging perspectives.

Medical oncology (Northwood, London, England)·2026
Same journal

Novel patient-derived tongue squamous cell carcinoma cell lines from non-smokers: 3D and in vivo models for drug response studies.

Medical oncology (Northwood, London, England)·2026
Same journal

Decoy oligonucleotide technology in cancer therapy: molecular mechanisms, challenges, and translational potential.

Medical oncology (Northwood, London, England)·2026
Same journal

The translational roles of circular RNAs in cancers and their underlying molecular mechanisms.

Medical oncology (Northwood, London, England)·2026
查看所有相关文章

相关实验视频

Updated: Jan 16, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.0K

工程采用细胞疗法用于固体瘤.

Maryam Sanjary1, Ameneh Shokati2, Mahshid Akhavan Rahnama3

  • 1Department of Clinical Biochemistry, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran.

Medical oncology (Northwood, London, England)
|September 27, 2025
PubMed
概括
此摘要是机器生成的。

适应性细胞疗法 (ACT) 对固体瘤有希望,克服了免疫抑制和抗原逃逸等挑战. 工程T细胞 (CAR-T,TCR-T,TILs) 使用CRISPR/Cas9等工具提高了个性化癌症治疗的疗效.

关键词:
适应性细胞疗法适应性细胞疗法在CAR T细胞中,在 NK 细胞中,NK 细胞是 NK 细胞.固体瘤是一种固体瘤.

更多相关视频

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

17.1K

相关实验视频

Last Updated: Jan 16, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

17.1K

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 生物技术是生物技术.

背景情况:

  • 适应性细胞疗法 (ACT) 在血液癌症中表现出成功,但在固体瘤中面临障碍.
  • 挑战包括免疫细胞透不良,多种瘤抗原和抑制性瘤微环境.

研究的目的:

  • 审查当前提高ACT在固体瘤中的疗效的策略.
  • 探索工程T细胞和基因编辑技术的进步.

主要方法:

  • 专注于工程T细胞:CAR-T,TCR-T和瘤透淋巴细胞 (TIL).
  • 讨论瘤向,克服免疫抑制和抗原逃逸的策略.
  • 突出了基因编辑工具,如CRISPR/Cas9用于下一代免疫细胞.

主要成果:

  • 工程T细胞证明了改善固体瘤治疗的潜力.
  • 克里斯普尔/Cas9促进了更具功能和更安全的免疫细胞的发展.
  • 工程和系统生物学的整合提高了ACT的能力.

结论:

  • ACT策略正在发展,以解决固体瘤的复杂性.
  • 下一代ACT对个性化癌症治疗具有重大前景.
  • 结合新技术的进一步研究对于临床翻译至关重要.